- Page 1 and 2:
Evidence Report/Technology Assessme
- Page 4 and 5:
PrefaceThe Agency for Healthcare Re
- Page 6 and 7:
Charles Inturrisi, Ph.D.Professor o
- Page 8 and 9:
Robert Jamison, Ph.D.Professor of A
- Page 10 and 11:
Conclusions. Evidence on long-term
- Page 12 and 13:
no opioid on: (1) opioid abuse, add
- Page 14 and 15:
References ........................
- Page 16 and 17:
The purpose of this report is to sy
- Page 18 and 19:
patient education, (3) urine drug s
- Page 20 and 21:
Each abstract was independently rev
- Page 22 and 23:
We rated the quality of each cohort
- Page 24 and 25:
ResultsOverviewThe search and selec
- Page 26 and 27:
Key Question 4. Risk Assessment and
- Page 28 and 29:
Table A. Summary of evidence (conti
- Page 30 and 31:
Table A. Summary of evidence (conti
- Page 32 and 33:
Table A. Summary of evidence (conti
- Page 34 and 35:
Evidence on the effectiveness of di
- Page 36 and 37:
ApplicabilityA number of issues cou
- Page 38 and 39:
the exception of buccal or intranas
- Page 40:
References1. International Associat
- Page 43 and 44:
outcome study of long-term opioid d
- Page 45 and 46:
patients? Pain Physician. 2006;9(1)
- Page 47 and 48:
American Academy of Pain Medicine,
- Page 49 and 50:
d. What is the comparative effectiv
- Page 51 and 52:
inclusion to English-language artic
- Page 53 and 54:
adequately reported and acceptable;
- Page 55 and 56:
eview comments will be made availab
- Page 57 and 58:
Key Question 1aIn patients with chr
- Page 59 and 60:
Key Question 2aIn patients with chr
- Page 61 and 62:
and F2). 49-58 All were rated fair-
- Page 63 and 64:
Table 1. Uncontrolled studies of lo
- Page 65 and 66: Table 1. Uncontrolled studies of lo
- Page 67 and 68: The annual overdose rate was 256 pe
- Page 69 and 70: The SOE for the association between
- Page 71 and 72: One fair-quality cross-sectional st
- Page 73 and 74: 5300 controls who did not visit the
- Page 75 and 76: Key Question 3cIn patients with chr
- Page 77 and 78: Table 2. Head-to-head trials and ob
- Page 79 and 80: Table 2. Head-to-head trials and ob
- Page 81 and 82: withdrawal due to opioid misuse, bu
- Page 83 and 84: Table 3. Trials of different strate
- Page 85 and 86: Table 3. Trials of different strate
- Page 87 and 88: • Two studies evaluated the Scree
- Page 89 and 90: Table 4. Studies of risk assessment
- Page 91 and 92: Detailed SynthesisThe APS review id
- Page 93 and 94: Evidence on the effectiveness of di
- Page 95 and 96: Table 6. Summary of evidence (conti
- Page 97 and 98: Table 6. Summary of evidence (conti
- Page 99 and 100: Table 6. Summary of evidence (conti
- Page 101 and 102: The setting in which studies were c
- Page 103 and 104: switching to other prescription opi
- Page 105 and 106: States: Fact Sheet. Atlanta, GA: Ce
- Page 107 and 108: overdose: a cohort study. Ann Inter
- Page 109 and 110: placebo-controlled study. Clin Ther
- Page 111 and 112: pain. Ann Intern Med. 2014;160(1):3
- Page 113 and 114: Appendix A. Search StrategiesDataba
- Page 115: 19. 18 and (random$ or control$ or
- Page 119 and 120: 3. (alfentanil or alphaprodine or b
- Page 121 and 122: 25. Risk Reduction Behavior/ or Ris
- Page 123 and 124: KQ 4a-4c: Risk Prediction and Mitig
- Page 125 and 126: "meperidine" OR "meptazinol" OR (MH
- Page 127 and 128: PICOT Include ExcludeOutcomes • F
- Page 129 and 130: Moore TM, Jones T, Browder JH, et a
- Page 131 and 132: Banning A, Sjogren P, Kaiser F. Rea
- Page 133 and 134: study. Pain. 2004;108(1-2):17-27. P
- Page 135 and 136: Edlund MJ, Sullivan M, Steffick D,
- Page 137 and 138: Gianutsos L, Safrenek S. Is there a
- Page 139 and 140: China. Addiction. 2011;106(10):1801
- Page 141 and 142: study. Compr Psychiatry. 1979;20(1)
- Page 143 and 144: 2009;10(4):531-43. PMID: 19243306.
- Page 145 and 146: Mercadante S, Casuccio A, Tirelli W
- Page 147 and 148: 2003;107(3):486-92. PMID: 14506751.
- Page 149 and 150: Quigley C. Hydromorphone for acute
- Page 151 and 152: osteoarthritis-related pain: placeb
- Page 153 and 154: 2013;7(2):96-101. PMID: 23385449. E
- Page 155 and 156: effect of maternal, postnatal, adol
- Page 157 and 158: Vestergaard P, Rejnmark L, Mosekild
- Page 159 and 160: Yulug B, Ozan E. Buprenorphine: a s
- Page 161 and 162: Author, YearType of StudySettingDur
- Page 163 and 164: Author, YearType of StudySettingDur
- Page 165 and 166: Author, YearType of StudySettingDur
- Page 167 and 168:
Author,yearDunn,2010ScreenedEligibl
- Page 169 and 170:
Author,yearGomes,2011ScreenedEligib
- Page 171 and 172:
Author,yearLi, 2013Method For Asses
- Page 173 and 174:
Author,yearMethod For AssessingOutc
- Page 175 and 176:
Appendix Table E4. Observational St
- Page 177 and 178:
Author, YearKQLi, 2013 KQ2a Case-Co
- Page 179 and 180:
Appendix Table E5. Observational St
- Page 181 and 182:
0Appendix Table E6. Observational S
- Page 183 and 184:
Appendix Table E7. Trials of Differ
- Page 185 and 186:
Appendix Table E8a. Head-to-Head Tr
- Page 187 and 188:
AuthorYearStudydesignDurationWild 2
- Page 189 and 190:
Author,YearHartung,2007Type of Stud
- Page 191 and 192:
Author,YearKrebs,2011Type of Study,
- Page 193 and 194:
AuthorYearStudyDesignDurationRCT12
- Page 195 and 196:
Author yearAshburn, 2011Study Desig
- Page 197 and 198:
Author yearPortenoy, 2007Study Desi
- Page 199 and 200:
Author yearSimpson, 2007Study Desig
- Page 201 and 202:
Author yearStudy designDurationCowa
- Page 203 and 204:
Author YearRalphs, 1994StudyDesignD
- Page 205 and 206:
Author,Year Study DesignAkbik 2006
- Page 207 and 208:
Author,YearWebster2005Study DesignP
- Page 209 and 210:
Appendix F. Quality Assessment Tabl
- Page 211 and 212:
Author,YearGomes,2011Gomes,2013KQKQ
- Page 213 and 214:
Evaluatespopulationother than theon
- Page 215 and 216:
Key QuestionOutcomeStudy DesignNumb
- Page 217 and 218:
Key QuestionOutcomeStudy DesignNumb
- Page 219:
Key Question Outcome4. Risk assessm